This content is created by Smallcaps Authors. [Author : Imelda Cotton]
Clinical stage cell therapy company Chimeric Therapeutics (ASX: CHM) has secured up to $10.1 million under a staged private placement over a 24-month period with US firm Lind Global Fund II. Lind will make an initial advance payment of $3.1 million for use as working capital to support Chimeric’s clinical trial pipeline and therapy portfolio. […]
The post Chimeric Therapeutics secures $12.6m to fund clinical trial pipeline appeared first on Small Caps.
from Small Caps https://ift.tt/cWkfUHx
Post a Comment